[Federal Register Volume 63, Number 105 (Tuesday, June 2, 1998)]
[Notices]
[Pages 30006-30007]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-14496]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing: DNA
Vaccines for Chlamydia Trachomatis
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications and issued patent listed below may be obtained by
contacting Robert Benson, Ph.D., Technology Licensing Specialist,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804;
telephone: (301) 496-7056 ext. 267; fax: (301) 402-0220; e-mail:
rb20m@nih.gov. A signed Confidential Disclosure Agreement will be
required to receive copies of the patent applications.
Nucleotide, Deduced Amino Acid Sequence, Isolation and Purification
of Heat-Shock Chlamydial Proteins
RB Morrison, HD Caldwell (NIAID)
Serial No. 07/531,317 Filed 31 May 90 (U.S. Patent 5,071,962 Issued 10
Dec. 91); Serial No. 07/841,323 Filed 25 Feb. 92 (Divisional of 07/
531,317); Serial No. 09/071,506 Filed 01 May 98 (Divisional of 07/
841,323)
This invention concerns the discovery of a novel gene that encodes
the HSP60 protein from Chlamydia trachomatis, referred to as HypB in
the application. This immunodominant protein is a major target for
Chlamydia trachomatis vaccine development and diagnostics. This gene
and protein, or fragments thereof, are useful in the development of
both recombinant protein and DNA based vaccines. The recombinant
protein or DNA sequence also have potential for the development of
diagnostic tests for C. trachomatis. The three patent properties claim
different aspects of the invention. The issued patent claims monoclonal
antibodies reactive against C. trachomatis HSP60 protein. Serial No.
07/841,323 claims the HSP60 protein and its use as a vaccine. Serial
No. 09/071,506 claims DNA sequences, and protein fragments thereof,
encoding HSP60. This DNA sequence would be useful in a DNA vaccine,
alone or with the MOMP DNA sequences claimed in Serial No. 07/853,359.
No foreign patent rights exist.
Nucleotide and Amino Acid Sequences of the Four Variable Domains of
the Major Outer Membrane Proteins of Chlamydia Trachomatis
H Caldwell et al. (NIAID)
Serial No. 07/853,359 Filed 16 Mar. 92 (With Priority to 17 Mar. 89)
Chlamydia trachomatis is the leading sexually transmitted
infectious agent in the United States, causing about 10 million new
cases per year. It is a major cause of involuntary infertility in
women. This invention claims the DNA sequences, and their encoded amino
acid sequences, of the four variable domains from the major outer
membrane protein (MOMP) of Chlamydia trachomatis, from the serovars Ba,
D, E, F, G, H, I, J, K, and L3. Serovars D, E, F, G, H, I, J, and K are
the most common serovars associated with Chlamydia trachomatis caused
sexually transmitted diseases. The claimed variable domains of MOMP
contain the major antigen targets of protective immunity including
neutralizing antibodies capable of preventing chlamydial infection.
Thus, these sequences are useful for the development of recombinant
protein, peptide, and DNA based vaccines
[[Page 30007]]
against C. trachomatis caused sexually transmitted diseases. The
variable domains also represent the primary serotyping antigenic
determinants of C. trachomatis organisms making these variable domain
sequences potential useful targets for the development of DNA or
antibody based diagnostic assays for C. trachomatis. The invention is
described further in Ying et al., Infection & Immunity 57, 1040-1049,
1989. Zhang et al., J. Infect. Dis. 176, 1035-1040, 1997 describes DNA
vaccines utilizing MOMP DNA.
Dated: May 21, 1998.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-14496 Filed 6-1-98; 8:45 am]
BILLING CODE 4140-01-M
